Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.

This difference was apparent in the sub-group analysis with the reason for discontinuation specified as lack of improvement/progression of disease (HR = 1.7, p = 10 −6 ), scheduled stop/convenience (HR = 1.6, p = 0.001) or without the reason recorded (HR = 1.5, p = 10 −16 ).

also in 830 other papers

[8] , [12] In the present study, we have shown a similar trend towards higher annual discontinuation rates due to adverse events/lack of tolerance in patients receiving Rebif in the higher dosage, however, this did not reach statistical significance.

also in 111,027 other papers